Verrica Pharmaceuticals Inc. reported total revenue of $14.3 million for the third quarter of 2025, including $3.6 million in YCANTH revenue and $10.7 million in license and collaboration revenue. For the nine months ended September 30, 2025, product revenue, net was $11.6 million, up from $6.3 million for the same period in 2024, primarily due to increased deliveries of YCANTH. License and collaboration revenue for the nine-month period was $18.9 million, compared to $1.0 million in the prior year, with $18.0 million attributed to milestone revenue from Torii. As of September 30, 2025, Verrica had $21.1 million in cash and cash equivalents. Recent business developments include positive feedback from the FDA regarding the Phase 3 program design for VP-315 in basal cell carcinoma, new data presented for VP-315, and a $10 million milestone payment received for the approval of YCANTH in Japan. The company also received supportive feedback from the European Medicines Agency for a Marketing Authorization Application filing for YCANTH for molluscum.